Objective: To investigate cyclooxygenase-2 (COX-2) expression of in colorectal carcinoma cell lines and tissues and its clinical implications.
Methods: SP immunohistochemistry was used to detect COX-2 protein in SW480 and SW620 cell lines and 50 primary colorectal carcinoma and 50 lymphoma metastasis carcinoma specimens. Real-time PCR was used to detect COX-2 mRNA expression in SW480 and SW620 cell lines.
Results: SW480 and SW620 cell lines both highly expressed COX-2. The positive expression levels of COX-2 increased significantly in lymph node metastatic carcinoma in comparison with primary colorectal carcinoma (P<0.05). The expression COX-2 mRNA in SW620 cell line was higher than that of SW480 cell line, showing a mean expression increment of 2.268 folds in SW620 cell line relative to SW480.
Conclusion: Elevated COX-2 expression may be associated with lymph node metastases of colorectal carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Epidemiology and anatomic distribution of colorectal cancer in South Africa.
S Afr J Surg
December 2024
Centre for Global Surgery, Department of Global Health, Stellenbosch University, South Africa.
Background: Colorectal cancer (CRC) is the fifth most common cancer in sub-Saharan Africa (SSA) and the third most common in South Africa (SA). CRC characteristics in SSA are not well described. The aim is to describe patient characteristics and anatomic location of colorectal adenocarcinoma (CRC-AC) in SA.
View Article and Find Full Text PDFGlobal trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019.
BMJ Oncol
September 2023
Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Objective: This study aimed to explore the global burden of early-onset cancer based on the Global Burden of Disease (GBD) 2019 study for 29 cancers worldwid.
Methods And Analysis: Incidence, deaths, disability-adjusted life years (DALYs) and risk factors for 29 early-onset cancer groups were obtained from GBD.
Results: Global incidence of early-onset cancer increased by 79.
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
BMJ Oncol
May 2024
Sarah Cannon Cancer Institute, Nashville, Tennessee, USA.
Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.
Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).
Identification of sulfonylated indolo[1,2-]quinolines as EGFR tyrosine kinase inhibitors.
RSC Adv
January 2025
Department of Chemistry, Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University Rama VI Road Bangkok 10400 Thailand
Two series of indolo[1,2-]quinolines (IQs), comprising six 6-trifluoromethylthio indolo[1,2-]quinolines and nine 6-arenesulfonyl indolo[1,2-]quinolines, were screened for their inhibitory activity against EGFR tyrosine kinase (EGFR-TK) using the ADP-Glo™ kinase assay. Among the 15 IQs screened, four compounds exhibited cytotoxic activity against a lung cancer cell line (A549) that was as potent as the known drug afatinib with lower cytotoxicity in Vero cells. In addition, while they displayed cytotoxic activity against a head and neck squamous cell carcinoma cell line (SCC cells), they were inactive against a colorectal cancer cell line (LS174T cells).
View Article and Find Full Text PDFReporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.
Future Sci OA
December 2025
Janssen Research & Development LLC, Raritan, NJ, USA.
Background: Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.
Methods: The National Library of Medicine's Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!